latest news releases from the newsroom
Kallelse till Årsstämma
Aktieägarna i The Empire Aktiebolag (publ)
kallas härmed till årsstämma måndagen den 31 mars 2008 kl. 11.30 på Regina
Teatern, Drottningsgatan 71 A, Stockholm
Registrering sker från kl. 11.00.
MorphoSys AG: AbD Serotec Receives Large Research Antibody Order From Proteomics Specialist Proteomika
MARTINSRIED, Germany, March 5, 2008 (PRIME NEWSWIRE) -- MorphoSys AG (FSE:MOR) (Prime Standard Segment:TecDAX) today announced that its AbD Serotec business unit has received a multiple research antibody order from Proteomika SL, a Spanish biotechnology company specializing in biomarker discovery. Proteomika has ordered novel, HuCAL-based, research antibodies against a broad range of target molecules in addition to the production of antigen material at AbD Serotec. AbD Serotec will apply MorphoSys's HuCAL GOLD antibody technology and the proprietary Antigen Expression System AgX(tm). The order ranks Proteomika among the largest customers for custom monoclonals services provided by AbD Serotec. Financial details of the agreement were not disclosed.
Nobel Biocare Strengthens Executive Management
ZURICH, Switzerland, March 5, 2008 (PRIME NEWSWIRE) -- Nobel Biocare announced today the appointment of Dr. Dirk Kirsten (39) as new Chief Financial Officer and member of the Executive Committee. He will assume his new role in the first half 2008. Kirsten, a Swiss/German citizen, will join Nobel Biocare from Syngenta where he has been Group Treasurer since 2005. Prior to that he was with Roche as Head of Group Funding & Capital Markets, Deutsche Bank as Director of Corporate Finance and PricewaterhouseCoopers. Dirk Kirsten has a broad background in finance and a proven track record in senior finance positions at large publicly listed companies. He holds a masters degree in economy from the University of Cologne and the London Business School, as well as a PhD in banking/management from the University of Cologne. Dirk Kirsten will replace Dr. Thomas Bogli, who has decided to pursue other opportunities outside the company.